These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 33586025

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ, Leeming DJ, Detlefsen S, Bruun MF, Hjuler ST, Henriksen K, Hein P, Karsdal MA, Brockbank S, Cruwys S.
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [Abstract] [Full Text] [Related]

  • 4. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
    Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ.
    Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
    [Abstract] [Full Text] [Related]

  • 5. The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.
    Flores-Costa R, Alcaraz-Quiles J, Titos E, López-Vicario C, Casulleras M, Duran-Güell M, Rius B, Diaz A, Hall K, Shea C, Sarno R, Currie M, Masferrer JL, Clària J.
    Br J Pharmacol; 2018 Mar; 175(6):953-967. PubMed ID: 29281143
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunction.
    Cheng C, Tan J, Qian W, Zhang L, Hou X.
    Life Sci; 2018 Sep 15; 209():157-166. PubMed ID: 30096384
    [Abstract] [Full Text] [Related]

  • 11. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 12. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA, Sheldon RD, Meers GM, Ortinau LC, Morris EM, Booth FW, Kanaley JA, Vieira-Potter VJ, Sowers JR, Ibdah JA, Thyfault JP, Laughlin MH, Rector RS.
    J Physiol; 2016 Sep 15; 594(18):5271-84. PubMed ID: 27104887
    [Abstract] [Full Text] [Related]

  • 13. Folic acid attenuates high-fat diet-induced steatohepatitis via deacetylase SIRT1-dependent restoration of PPARα.
    Xin FZ, Zhao ZH, Zhang RN, Pan Q, Gong ZZ, Sun C, Fan JG.
    World J Gastroenterol; 2020 May 14; 26(18):2203-2220. PubMed ID: 32476787
    [Abstract] [Full Text] [Related]

  • 14. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
    Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, Ito T, Katsume A, Sudoh M.
    Int J Exp Pathol; 2013 Apr 14; 94(2):93-103. PubMed ID: 23305254
    [Abstract] [Full Text] [Related]

  • 15. Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non-alcoholic steatohepatitis in rats.
    Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E.
    Toxicol Appl Pharmacol; 2020 Aug 15; 401():115101. PubMed ID: 32512072
    [Abstract] [Full Text] [Related]

  • 16. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G.
    J Transl Med; 2015 Jun 16; 13():193. PubMed ID: 26077675
    [Abstract] [Full Text] [Related]

  • 17. The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
    Schumacher JD, Kong B, Pan Y, Zhan L, Sun R, Aa J, Rizzolo D, Richardson JR, Chen A, Goedken M, Aleksunes LM, Laskin DL, Guo GL.
    Toxicol Appl Pharmacol; 2017 Sep 01; 330():1-8. PubMed ID: 28673684
    [Abstract] [Full Text] [Related]

  • 18. Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis.
    Lan T, Xu T, Fu Y, Jiang S, Liang X, Yu Z, Pan L, Rong X, Guo J.
    Front Endocrinol (Lausanne); 2022 Sep 01; 13():864703. PubMed ID: 35784533
    [Abstract] [Full Text] [Related]

  • 19. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T, Briand F, Trenteseaux C, Merian J, Combes G, Najib S, Sulpice T, Martinez LO.
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct 01; 317(4):G508-G517. PubMed ID: 31460789
    [Abstract] [Full Text] [Related]

  • 20. C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis.
    Bae CR, Hino J, Hosoda H, Miyazato M, Kangawa K.
    Life Sci; 2018 Sep 15; 209():349-356. PubMed ID: 30114411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.